Business Context and Reporting Period
Company: N2OFF, Inc. (Ticker: NITO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2025
Business Overview: N2OFF operates through two primary segments: (1) Pathogen prevention and shelf-life extension for fresh produce via its subsidiary Save Foods Ltd., and (2) Renewable energy projects, including solar photovoltaic and battery storage initiatives, primarily through joint ventures and subsidiaries like NITO Renewable Energy, Inc. The company is a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $66,000 | $44,000 |
| Gross Profit | $52,000 | $16,000 |
| Operating Loss | $(619,000) | $(899,000) |
| Net Loss | $(1,257,000) | $(822,000) |
| Net Loss Attributable to Stockholders | $(1,193,000) | $(769,000) |
| Cash and Cash Equivalents | $2,724,000 | $2,185,000 |
| Total Assets | $7,365,000 | $5,465,000 |
| Total Liabilities | $3,667,000 | $892,000 |
| Working Capital | $3,359,000 | $3,861,000 |
Key Balance Sheet Items:
- Debt: Credit facility liability of $764,000 (fair value) and various loans to affiliates (MitoCareX, Solterra).
- Warrant Liabilities: Significant non-cash liabilities totaling $2,327,000 ($415,000 current + $1,912,000 non-current) due to fair value accounting on warrants issued in recent financings.
- Investments: $782,000 in Plantify Foods and $1,252,000 in solar photovoltaic joint ventures.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 50% to $66,000, driven by increased sales to a US client.
- Cost Reductions: Cost of sales decreased 50% to $14,000, largely due to the absence of a prior-year inventory write-off in Turkey and reduced salaries. R&D expenses dropped 83% to $20,000 due to reduced professional fees for NTWO OFF activities.
- Net Loss Expansion: Net loss increased 53% to $1.257 million. This was primarily driven by $813,000 in financing expenses (net), compared to $5,000 income in the prior year. The financing expense surge is attributed to fair value adjustments on warrant liabilities and credit facilities.
- Balance Sheet Shift: Total liabilities increased significantly from $892,000 to $3,667,000, driven by the recognition of warrant liabilities and new credit facility draws.
- Capital Structure: Shares outstanding increased from ~12 million to ~17.8 million due to a PIPE transaction and warrant exercises.
Guidance, Outlook, Risks, and Unusual Items
Going Concern: The company has an accumulated deficit of $35.7 million and expects to continue generating losses. Management states there is substantial doubt about the company's ability to continue as a going concern, though they believe current cash will fund operations through Q4 2025. Additional financing is required.
Unusual Items:
- Non-Cash Fair Value Adjustments: Significant non-cash losses and gains were recorded due to the fair value option election on financial instruments. This includes an $8.1 million non-cash loss on initial warrant recognition and subsequent $7 million non-cash gain on revaluation.
- Financing Expenses: Financing expenses of $813,000 were driven by changes in the fair value of PIPE warrant liabilities and credit facilities, rather than traditional interest costs.
Risks and Contingencies:
- Geopolitical Risk: Operations are heavily concentrated in Israel. Ongoing conflicts with Hamas, Hezbollah, and regional instability pose significant risks to operations, personnel, and asset value.
- Acquisition Contingencies: A proposed acquisition of MitoCareX Bio Ltd. is pending stockholder approval. The deal involves issuing 40% of the company's fully diluted capital stock.
- Divestiture: The company sold 100% of its interest in NTWO OFF Ltd. in April 2025 for NIS 15,000.
Recent Developments (Post-Period):
- Entered a $3 million purchase agreement with YA II PN, Ltd. for convertible notes, contingent on SEC registration effectiveness.
- Issued significant equity grants to executives and consultants in May 2025.
Investor Verification Checklist
- Going Concern Status: Verify the timeline for securing additional financing to extend operations beyond Q4 2025.
- Warrant Liability Volatility: Assess the impact of future stock price fluctuations on the $2.3 million warrant liability, which directly impacts net income via fair value adjustments.
- MitoCareX Acquisition: Confirm the status of stockholder approval for the MitoCareX deal, which would result in massive dilution (40% of fully diluted shares).
- Israel Operations: Monitor the geopolitical situation in Israel and its specific impact on Save Foods Ltd. and personnel safety.
- Revenue Concentration: Investigate the dependency on the single US client driving the 50% revenue increase.